by Sylvia Kusemererwa, Sheila Kansiime, Gertrude Mutonyi, Ayoub Kakande, Shamim Nabukenya, Aeron Namirembe, Naphtal Erima, Doreen Joan Asio, Elizabeth Mbabazi Atuhura, Shamim Ssendagire, Martin Onyango, Julie Fox, Sheena McCormack, Pontiano Kaleebu, Eugene Ruzagira, on behalf of the PrEPVacc Study Team Introduction Despite global reports of declining HIV incidence, current data are limited. This study presents findings on HIV incidence and risk factors in a HIV trial preparedness cohort.
Methods Between 18 July 2018 and 13 October 2022, individuals 18–45-year-old were recruited from communities along the trans-African highway and the shores of Lake Victoria in Masaka district, Uganda. Eligible individuals were HIV-negative and met at least one of the following criteria: suspected or confirmed sexually transmitted infection (STI), unprotected sex with ≥2 partners, unprotected sex with a new partner in the past 3 months, or unprotected sex in exchange for money/goods in the past month.
Baseline data included demographics, sexual behaviour, and HIV risk factors.
PLOS ONE (Medicine) published a clinical update in Research Highlights on 08 May 2026.
The item focuses on Estimating HIV incidence and assessing associated risk factors among adults: Evidence from the 2018–2022 HIV vaccine preparedness cohort in Masaka, Uganda.
Review the original article for the full source wording and details.